Loading
Life sciences · Journal article
Onco · October 13, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Modern pipelines integrating multi-omics data, chemical libraries, structural biology information and artificial intelligence are currently accelerating drug discovery and precision medicine. Aligned with these advances, the multi-omics profiling technologies enable the identification of unique genetic and epigenetic signatures for stratification of patients based on cancer specific target and vulnerability. Targeted therapies to specific receptor or enzyme mutated or overexpressed often fail because cancer cells can adapt quickly. Tumor cells overgrow driven by new gene mutation and parallel crosstalk of signaling pathways. Patients with cancer and the hereditary syndrome targets such as BRCA1/2, and emerging targets such as ATR, CHK1, WEE1, and POLθ, are hypersensitive to ionizing radiation and PARP inhibitors. Combining synthetic lethality inhibitors, chemotherapy and immunotherapy effectively kill cancer cells by breaking multiple survival signaling pathways. Antibodies to immune checkpoint inhibitors targeting molecules like PD-1, PD-L1, and CTLA-4 can improve survival of patients, though predictive immunotype remains challenging. Emerging pharmacological approaches combining either epigenetic modifiers, oncomicrobiotics or engineered bacteria sequentially convert tumors into a highly antigenic, T cell-inflamed, and checkpoint-responsive tumor, providing a mechanistically grounded framework for next-generation precision immunotherapy. However, large human clinical trials remain necessary to standardize protocols, biomarkers and long-term efficacy. Cancer vaccines have evolved through rational engineering synthetic mRNA encoding tumor-specific antigens or tumor-associated antigens. This will enable the next generation of truly therapeutic and preventive vaccines for many cancers. This review provides a timely synthesis of the basic mechanisms for rational multidrug treatments for cancers.